AMAG Pharmaceuticals, Inc. (AMAG) Receives Average Rating of “Hold” from Analysts

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has received a consensus rating of “Hold” from the sixteen research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $21.00.

AMAG has been the topic of several research analyst reports. Jefferies Group reissued a “buy” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Sunday, November 5th. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Wednesday, October 4th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Piper Jaffray Companies reissued a “hold” rating and set a $15.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, January 18th. Finally, B. Riley reissued a “hold” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Tuesday, January 16th.

Shares of AMAG Pharmaceuticals (AMAG) traded down $0.20 during midday trading on Friday, hitting $14.45. The stock had a trading volume of 593,697 shares, compared to its average volume of 784,478. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $25.20. The firm has a market cap of $509.92, a price-to-earnings ratio of -2.38 and a beta of 0.79.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%. sell-side analysts forecast that AMAG Pharmaceuticals will post -6.05 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMAG. State Street Corp increased its position in AMAG Pharmaceuticals by 10.6% during the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after buying an additional 267,873 shares during the period. Tocqueville Asset Management L.P. acquired a new position in AMAG Pharmaceuticals during the third quarter worth approximately $3,958,000. Prudential Financial Inc. increased its position in AMAG Pharmaceuticals by 35.7% during the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after buying an additional 190,660 shares during the period. Dimensional Fund Advisors LP increased its position in AMAG Pharmaceuticals by 18.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in AMAG Pharmaceuticals by 46.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock worth $7,839,000 after buying an additional 134,080 shares during the period.

COPYRIGHT VIOLATION WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) Receives Average Rating of “Hold” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/27/amag-pharmaceuticals-inc-amag-receives-average-rating-of-hold-from-analysts.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply